Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Current Deferred Revenue: 2015-2018

Historic Current Deferred Revenue for Outlook Therapeutics (OTLK) over the last 4 years, with Sep 2018 value amounting to $1.7 million.

  • Outlook Therapeutics' Current Deferred Revenue rose 5.80% to $2.3 million in Q2 2019 from the same period last year, while for Jun 2019 it was $2.3 million, marking a year-over-year increase of 5.80%. This contributed to the annual value of $1.7 million for FY2018, which is 43.69% down from last year.
  • Latest data reveals that Outlook Therapeutics reported Current Deferred Revenue of $1.7 million as of FY2018, which was down 43.69% from $3.1 million recorded in FY2017.
  • In the past 5 years, Outlook Therapeutics' Current Deferred Revenue ranged from a high of $3.1 million in FY2017 and a low of $1.2 million during FY2016.
  • Over the past 3 years, Outlook Therapeutics' median Current Deferred Revenue value was $1.7 million (recorded in 2018), while the average stood at $2.0 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 154.63% in 2017, then tumbled by 43.69% in 2018.
  • Outlook Therapeutics' Current Deferred Revenue (Yearly) stood at $2.0 million in 2015, then tumbled by 38.75% to $1.2 million in 2016, then surged by 154.63% to $3.1 million in 2017, then crashed by 43.69% to $1.7 million in 2018.